PMID- 28120600
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20170912
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 49
IP  - 1
DP  - 2017 Jan
TI  - Immediate adverse reactions to intravenous immunoglobulin in children: a single 
      center experience.
PG  - 11-14
AB  - Intravenous immunoglobulin (IVIG) is commonly used in primary and secondary 
      immunodeficiency diseases as well as autoimmune conditions as immunomodulatator 
      treatment. Immediate adverse events which are generally mild and occur during 
      infusion are seen in 6 hours. Reported immediate adverse events are in a wide 
      range from 1%-40% in pediatric patients. 115 patients who received IVIG (except 
      newborns) were included into this crosssectional study. IVIG was given to 
      patients for primary immunodeficiencies (n=8), ITP (n=65), Kawasaki disease 
      (n=11), secondary immunosupression (n=28), and passive immunization (n=3). 5%, 
      10% IVIG preparations and pentaglobin were used. Headache, fever, chills, nausea, 
      rash, arthralgia, myalgia and back pain were accepted as mild immediate events. 
      There were 62 (54%) boys and 53 (46%) girls aged 1 month-18 years. Mean age of 
      the group was 7.4+/-4.6 years. Immediate adverse events due to IVIG infusions were 
      seen in 29 (25.2%) of all patients. Gender and types of the disease were not 
      different in significance regarding the presence of adverse events. The rate of 
      adverse events did not change with receiving pre-medication. The most common 
      reaction was fever/chills. Immediate reactions were seen in first 6 hours in 7 
      patients and during infusion in the remaining. They were treated with slowing of 
      the infusion rate and infusion was stopped in 3 patients because of moderate 
      events. Because of the increasingly use of IVIG therapy, it is important to know 
      the side effects. High doses, high infusion rates, accompanying infection may 
      worsen the adverse effects especially in primary immunodeficiency diseases.
FAU - Kaba, S
AU  - Kaba S
AD  - Yuzuncu Yil University, School of Medicine, Deparment of Pediatrics, Van, Turkey.
FAU - Keskindemirci, G
AU  - Keskindemirci G
AD  - Kanuni Sultan Suleyman Research and Training Hospital, Department of Pediatric 
      Allergy-Immunology, Istanbul, Turkey.
FAU - Aydogmus, C
AU  - Aydogmus C
AD  - Kanuni Sultan Suleyman Research and Training Hospital, Department of Pediatric 
      Allergy-Immunology, Istanbul, Turkey.
FAU - Siraneci, R
AU  - Siraneci R
AD  - Kanuni Sultan Suleyman Research and Training Hospital, Department of Pediatric 
      Allergy-Immunology, Istanbul, Turkey.
FAU - Erol Cipe, F
AU  - Erol Cipe F
AD  - Kanuni Sultan Suleyman Research and Training Hospital, Department of Pediatric 
      Allergy-Immunology, Istanbul, Turkey. E-mail: ferol76tr@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects
MH  - Infant
MH  - Male
OTO - NOTNLM
OT  - Intravenous immunoglobulin
OT  - adverse events
EDAT- 2017/01/26 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/01/26 06:00
PHST- 2017/01/26 06:00 [entrez]
PHST- 2017/01/26 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2017 Jan;49(1):11-14.